Abstract | OBJECTIVE: METHODS: As part of an open trial, recombinant-methionyl-human leptin was given daily for 4 months to children who did not have diabetes and had Berardinelli-Seip congenital lipoatrophy and metabolic complications at a dosage that was meant to achieve physiologic levels. Six boys and 1 girl (age: 2.4-13.6 years), with a mean fasting insulin level of >15 mIU/L and hypertriglyceridemia, were included. RESULTS: CONCLUSIONS:
Leptin replacement is able to reverse metabolic complications in the majority of children with Berardinelli-Seip congenital lipoatrophy and with insulin resistance or dyslipidemia before the development of overt diabetes.
|
Authors | Jacques Beltrand, Marta Beregszaszi, Didier Chevenne, Guy Sebag, Marc De Kerdanet, Frédéric Huet, Michel Polak, Nadia Tubiana-Rufi, Didier Lacombe, Alex M De Paoli, Claire Levy-Marchal |
Journal | Pediatrics
(Pediatrics)
Vol. 120
Issue 2
Pg. e291-6
(Aug 2007)
ISSN: 1098-4275 [Electronic] United States |
PMID | 17671040
(Publication Type: Clinical Trial, Phase II, Comparative Study, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
|
Topics |
- Adolescent
- Child
- Child, Preschool
- Female
- Humans
- Leptin
(deficiency, metabolism, therapeutic use)
- Lipodystrophy, Congenital Generalized
(blood, drug therapy, metabolism)
- Male
- Prospective Studies
|